Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Digestive diseases and sciences - 1 Feb 2015

Moon Chansoo, Jung Kyu Sik, Kim Do Young, Baatarkhuu Oidov, Park Jun Yong, Kim Beom Kyung, Kim Seung Up, Ahn Sang Hoon, Han Kwang-Hyub

Abstract excerpt

BACKGROUND: To elucidate the benefits of successful antiviral therapy in chronic hepatitis C (CHC) patients METHODS: A total of 463 CHC patients who underwent pegylated interferon alfa and ribavirin therapy were classified as sustained virological response (SVR) or non-SVR based on response to antiviral therapy. We investigated disease progression to cirrhosis in non-cirrhotic patients, development of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Protective Factors

Share to Republic of Korea

Share to Ribavirin

Source

Identifiers

PMID: 25236421
DOI: 10.1007/s10620-014-3361-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.PMID 25236421Read ↗

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.Semantic proximity Read ↗

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.Semantic proximity Read ↗

Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.Semantic proximity Read ↗

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.Semantic proximity Read ↗

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.Semantic proximity Read ↗

Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.Semantic proximity Read ↗

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of EpigeneticsSemantic proximity Read ↗

How sustained is sustained viral response in patients with hepatitis C virus infection?Semantic proximity Read ↗

DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C DO NOT AFFECT THE RISK OF DEVELOPMENT OR THE OUTCOME OF HEPATOCELLULAR CARCINOMA.Semantic proximity Read ↗

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.